The cellular prion protein PrP^C^, encoded by the *Prnp* gene, is tethered to the membrane of most mammalian cells by a glycosylphosphatidylinositol anchor. Conversion and aggregation of PrP^C^ into a misfolded conformer (termed PrP^Sc^) triggers transmissible spongiform encephalopathies, also termed prion diseases ([@bib1]). Disparate functions have been ascribed to PrP^C^ on the basis of phenotypes described in *Prnp^−/−^* mice ([@bib67]; [@bib43]), yet none of these functions has been clarified mechanistically, and their validity was frequently challenged.

All currently available *Prnp^−/−^* lines were generated using embryonic stem (ES) cells derived from the 129 strain of *Mus musculus*. Typically, chimeric founder mice were crossed with WT (*Prnp^wt/wt^*) mice of the C57BL/6 strain (B6; [Table 1](#tbl1){ref-type="table"}). The resulting mice carrying the targeted allele were maintained as a mixed B6/129 background (B6129) or backcrossed to inbred strains (mainly B6), often for \>10 generations, to generate congenic B6.129 mice (the period in B6.129 denotes congenesis, as opposed to mixed B6129 mice). Although the latter approach progressively reduces the contribution of the 129-derived genome, *Prnp*-linked genomic intervals may co-segregate with *Prnp* ([@bib66]). Consequently, congenic *Prnp^wt/wt^* and *Prnp^−/−^* mice may differ at additional polymorphic loci ([@bib65]; [@bib23]). We hypothesized that co-segregation of linked genes may have confounded the attribution of functions to PrP^C^ based on phenotypes observed in *Prnp^−/−^* mice ([@bib11]; [@bib44]; [@bib77]; [@bib57]; [@bib39]; [@bib6]; [@bib24]; [@bib58]; [@bib68]).

###### 

*Prnp* KO mouse lines analyzed in this study

  *Prnp* KO mouse line    ES cells   Origin of ES cells   Strain of partner of chimeric mouse   Location of colony        Reference
  ----------------------- ---------- -------------------- ------------------------------------- ------------------------- -----------
  *Prnp^ZrchI/ZrchI^*     AB1        129S7/SvEvBrd        B6                                    Zurich, Switzerland       [@bib5]
  *Prnp^Ngsk/Ngsk^*       J1         129S4/SvJae          B6                                    Nagasaki, Japan           [@bib61]
  *Prnp^Edbg/Edbg^*       E14        129/Ola              129/Ola                               Edinburgh, Scotland, UK   [@bib45]
  *Prnp^GFP/GFP^*         HM-1       129/Ola              B6                                    Cambridge, MA             [@bib26]
  *Prnp^Rkn/Rkn^*         E14        129P2/OlaHsd         B6                                    Wako-shi, Japan           [@bib80]
  *Prnp^ZrchII/ZrchII^*   E14.1      129/OlaHsd           B6                                    Zurich, Switzerland       [@bib60]
  *Prnp^Rcm0/Rcm0^*       HM-1       129/Ola              129/Ola                               Edinburgh, Scotland, UK   [@bib47]

The present study is based on the analysis of mice carrying seven independently generated *Prnp*-null alleles. *Prnp^Edbg/Edbg^* and *Prnp^Rcm0/Rcm0^* were always crossed to isogenic 129/Ola mice, whereas all other *Prnp^−/−^* mice were crossed to B6 mice and then kept on a mixed B6 and 129 background or further backcrossed to B6 or other strains.

Here we selected a cell-autonomous phenotype previously reported in congenic B6.129-*Prnp^ZrchI/ZrchI^* mice ([@bib5]): inhibition of phagocytosis of apoptotic cells ([@bib14]). We used RNA sequencing to identify genes linked to *Prnp* and expressed in macrophages that may influence this phenotype. We report genetic and functional evidence that the regulation of phagocytosis previously ascribed to *Prnp^−/−^* is instead controlled by the closely linked gene *signal regulatory protein α* (*Sirpa*; [@bib46]).

RESULTS
=======

RNA sequencing indicates *Sirpa* as a candidate modulator of phagocytosis
-------------------------------------------------------------------------

Because hyperphagocytosis was reported in *Prnp^ZrchI/ZrchI^* mice after extensive backcrossing to B6, we reasoned that any genetic confounders leading to this phenotype in B6.129-*Prnp^ZrchI/ZrchI^* mice would need to be physically linked to *Prnp*, polymorphic between 129 and B6 strains, and expressed in macrophages. To identify such genes, we performed RNA sequencing on B6.129-*Prnp^ZrchI/ZrchI^* and B6.129-*Prnp^wt/wt^* peritoneal macrophages (pMΦs). Of 11,586 genes, 305 were differentially expressed between the two groups ([Fig. 1 A](#fig1){ref-type="fig"} and [Table S1](http://www.jem.org/cgi/content/full/jem.20131274/DC1){#supp1}). We then analyzed the reads for the presence of deviations from the B6 reference transcriptome ([Fig. 1 B](#fig1){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}) and applied a step-wise filtering strategy to narrow down potential confounding candidate genes ([Fig. 1 C](#fig1){ref-type="fig"}). B6.129-*Prnp^ZrchI/ZrchI^* pMΦs showed significantly more deviations from the B6 reference than did B6.129-*Prnp^wt/wt^* ([Fig. 1 B](#fig1){ref-type="fig"} and [Table 2](#tbl2){ref-type="table"}). By plotting the density of sequence variations in B6.129-*Prnp^ZrchI/ZrchI^* pMΦ mRNA against their physical location, we observed clustering of variants on chromosome 2 (Chr 2) around *Prnp* at 128--156 Mbp ([Fig. 1 B](#fig1){ref-type="fig"}).

![**RNA sequencing identifies macrophage-expressed genes potentially controlling phagocytosis in *Prnp^ZrchI/ZrchI^* versus *Prnp^wt/wt^* mice.** (A) mRNA heat map highlighting 305 differentially expressed genes between B6.129-*Prnp^ZrchI/ZrchI^* and B6.129-*Prnp^wt/wt^* (pMΦs, three mice per group), ordered by chromosomal location (vertical) and unsupervised hierarchical clustering (horizontal). Chr 2 (in yellow) contains significantly more differentially expressed genes (P = 0.0011, based on Z score \> 44 and corrected for chromosome size). Individual genes are listed in [Table S1](http://www.jem.org/cgi/content/full/jem.20131274/DC1){#supp2}. (B) Physical distribution of SNPs unique to the B6.129-*Prnp^ZrchI/ZrchI^* pMΦ transcriptome clustered on Chr 2 (in yellow; two-tailed Student's *t* test, P = 0.019) at 128--156 Mbp. (C) Filtering strategy to prioritize genes controlling phagocytosis in *Prnp^ZrchI/ZrchI^* versus *Prnp^wt/wt^* mice. Sequential filters were applied to a total of 22,981 SNPs differing between the B6.129-*Prnp^ZrchI/ZrchI^* and B6.129-*Prnp^wt/wt^* pMΦ transcriptomes. SNPs affecting protein coding sequence included nonsynonymous SNPs and insertions/deletions. The asterisk indicates phenotypic definition based on gene ontology annotations and PubMed searches. *Sirpa*, *Mertk*, *Thbs1*, and *Tyro3* display nonsynonymous SNPs between B6.129-*Prnp^ZrchI/ZrchI^* and B6.129-*Prnp^wt/wt^* mice, reside on Chr 2, and are involved in phagocytosis. However, only *Sirpa* (purple) is known to display polymorphisms that modulate phagocytosis.](JEM_20131274_Fig1){#fig1}

###### 

Summary statistics of RNA sequencing

  Mouse    Total reads   Mapped reads         Mean coverage   \# SNPs   \# Het. SNPs   \# Hom. SNPs   \# Indels   \# Nonsyn. variants   \# Nonsyn. variant genes
  -------- ------------- -------------------- --------------- --------- -------------- -------------- ----------- --------------------- --------------------------
  WT 1     58,838,924    56,801,099 (96.5%)   58.6x           102,465   14,249         88,216         6,860       2,902                 362
  WT 2     56,971,575    55,447,441 (97.3%)   60.1x           102,756   12,591         90,165         7,451       2,874                 361
  WT 3     77,632,102    75,325,378 (97.0%)   67.4x           117,354   15,501         101,853        8,356       3,360                 415
  All WT                                                      84,205    9,535          74,670         5,644       2,277                 197
  KO 1     71,507,393    69,906,771 (97.8%)   64.6x           117,979   15,146         102,833        8,164       3,517                 466
  KO 2     70,456,814    68,728,168 (97.5%)   62.7x           114,906   14,943         99,963         8,185       3,391                 466
  KO 3     75,295,650    73,039,778 (97.0%)   65.4x           117,592   15,539         102,053        8,405       3,515                 488
  All KO                                                      92,176    9,569          82,607         6,397       2,682                 264

WT, B6.129-*Prnp^wt/wt^*; KO, B6.129-*Prnp^ZrchI/ZrchI^*; \#, number; Het., heterozygous; Hom., homozygous; Indels, insertions/deletions; Nonsyn., nonsynonymous.

Of all genes transcribed in pMΦs, 132 showed nonsynonymous coding variants between B6.129-*Prnp^wt/wt^* and B6.129-*Prnp^ZrchI/ZrchI^* ([Fig. 1 C](#fig1){ref-type="fig"} and [Table S2](http://www.jem.org/cgi/content/full/jem.20131274/DC1){#supp3}). Of these, 62 mapped to Chr 2, 4 of which, *Sirpa* ([@bib46]; [@bib8]), *Mertk* ([@bib63]), *Tyro3* ([@bib64]), and *Thbs1* ([@bib22]), had been previously described to impact phagocytosis ([Fig. 1 C](#fig1){ref-type="fig"}).

Of these four candidate genes, *Sirpa* ([Fig. 1 C](#fig1){ref-type="fig"}) encodes the transmembrane SIRPα, is closely linked to *Prnp* (≈2.2 Mbp), is highly polymorphic in laboratory mice ([@bib62]), and, uniquely among the four candidates, displays polymorphisms with robust modulatory effects on phagocytosis ([@bib71]; [@bib40]; [@bib70]; [@bib72]; [@bib79]). Binding of CD47 on cognate cells to SIRPα on macrophages transmits a "don't eat me" signal that protects the targets from phagocytosis ([@bib46]; [@bib8]). Down-regulation of CD47 cell surface expression on ageing or apoptotic cells enhances their phagocytosis ([@bib3]; [@bib46]). Polymorphisms of the Ig-like amino-terminal domain of SIRPα can affect CD47 binding and modulate phagocytosis ([@bib71]; [@bib40]; [@bib70]; [@bib72]). These characteristics led us to prioritize *Sirpa* as the most plausible candidate for modifying the phagocytic phenotype described in B6.129-*Prnp^ZrchI/ZrchI^* versus B6.129-*Prnp^wt/wt^* mice.

*Sirpa^129^* segregates with *Prnp^−^* in seven *Prnp^−/−^* lines
-----------------------------------------------------------------

We then analyzed *Sirpa* alleles in *Prnp^ZrchI/ZrchI^* mice and in six additional, independently generated mouse lines carrying targeted *Prnp* deletions ([Table 1](#tbl1){ref-type="table"}, [Fig. 2](#fig2){ref-type="fig"}, and [Fig. S1](http://www.jem.org/cgi/content/full/jem.20131274/DC1){#supp4}). Restriction fragment length polymorphism (RFLP) analysis and DNA sequencing revealed that the targeted *Prnp* allele co-segregated with the *Sirpa* allele of the 129 strain (*Sirpa^129^*) in *Prnp^ZrchI/ZrchI^* mice that had been backcrossed \>17 generations to BALB/c (C) or for \>12 generations to B6 mice in our colony ([Fig. 2](#fig2){ref-type="fig"}). We also observed co-segregation of *Prnp* and *Sirpa* alleles in *Prnp^ZrchI/ZrchI^* mice backcrossed for 12 generations to B6 and in *Prnp^Edbg/Edbg^* backcrossed for ≤18 generations to B6 mice from four different laboratories ([Figs. S1 and S2](http://www.jem.org/cgi/content/full/jem.20131274/DC1){#supp5} and not depicted). Similar results were observed for alleles at *Mertk*, *Tyro3*, and *Thbs1*, with the exception of an independently generated congenic *Prnp^−/−^* line called "Ngsk" ([Table 1](#tbl1){ref-type="table"} and [Table S3](http://www.jem.org/cgi/content/full/jem.20131274/DC1){#supp6}). Congenic B6.129-*Prnp^Ngsk/Ngsk^* mice have the genotypes *Sirpa^129/129^ Mertk^129/129^ Tyro3^B6/B6^ Thbs1^B6/B6^,* likely reflecting a recombination event during repeated backcrossing to B6 mice. Thus, *Sirpa* and/or another of the three genes could affect the hyperphagocytosis phenotype reported in *Prnp^ZrchI/ZrchI^* mice ([@bib14]).

![***Sirpa* allelotype of the *Prnp^−/−^* lines analyzed in this study.** (A) RFLP analysis of *Sirpa* allelotypes. The *Sirpa^129^* allele segregates with the *Prnp^−^* allele in *Prnp^−/−^* mouse lines stemming from seven independent targeting events (see [Table 1](#tbl1){ref-type="table"}). The 8th through 11th lanes show respective reference strain DNA. (B) The red box indicates protein sequence alignment of mouse SIRPα Ig-like variable domain (IgV) confirming the 129 *Sirpa* allelotype in each one of the seven *Prnp^−/−^* lines shown in A. The blue box indicates SIRPα protein reference sequences for the B6, 129/Sv, and 129/Ola strains. Polymorphisms are highlighted in yellow. For each group one mouse was analyzed.](JEM_20131274_Fig2){#fig2}

Functional analysis excludes *Prnp* and points to *Sirpa* as the gene controlling phagocytosis
----------------------------------------------------------------------------------------------

We then sought to determine the contribution of polymorphic *Prnp*-flanking genes to the phagocytic phenotype of *Prnp^−/−^* mice. The phagocytic activity of primary macrophages was compared between *Prnp^wt/wt^* and three different strains of *Prnp^−/−^* mice differing at all four, two, or none of the closely linked polymorphic genes. When offered apoptotic thymocytes as targets, B6.129-*Prnp^ZrchI/ZrchI^* pMΦs displayed higher rates of phagocytosis than those from heterozygous B6.129-*Prnp^wt/ZrchI^* or WT B6.129-*Prnp^wt/wt^* congenic littermates ([Fig. 3, A and B](#fig3){ref-type="fig"}, left) in agreement with a previous study ([@bib14]). We also observed this hyperphagocytic phenotype in BMDMs of B6.129-*Prnp^ZrchI/ZrchI^* and B6.129-*Prnp^Ngsk/Ngsk^* mice ([Fig. 3 B](#fig3){ref-type="fig"}, middle). In contrast, pMΦs from 129-*Prnp^Edbg/Edbg^* mice ([Fig. 3 A](#fig3){ref-type="fig"}, right; [@bib45]) displayed similar phagocytic activity as 129-*Prnp^wt/wt^* pMΦs ([Fig. 3 B](#fig3){ref-type="fig"}, right). 129-*Prnp^Edbg/Edbg^* were generated from 129 ES cells and maintained as a co-isogenic 129 line ([Fig. 3 A](#fig3){ref-type="fig"}, right). The two strains showed no differences in microsatellite markers linked to *Prnp* ([Fig. 3 C](#fig3){ref-type="fig"}). Consequently, ablation of *Prnp* was insufficient to drive hyperphagocytosis, suggesting the influence of additional genetic elements in *Zrchl* and *Ngsk* mice.

![**Ablation of *Prnp* is not sufficient to enhance phagocytosis of apoptotic cells.** (A) Generation of B6.129 congenic (left) and 129 co-isogenic (right) *Prnp^−/−^* lines. In B6.129 congenic mice, residual 129 genomic material derived from the ES cell (brown) is inevitably present, particularly in the region flanking the targeted locus. (B, left) pMΦs from congenic B6.129-*Prnp^ZrchI/ZrchI^* mice showed higher phagocytic activity than those from B6.129-*Prnp^wt/wt^* (set as 100%) and B6.129-*Prnp^wt/ZrchI^* littermates. Blue, black, and gray (here and henceforth) indicate data from independent experiments. (middle) B6.129-*Prnp^ZrchI/ZrchI^* and B6.129-*Prnp^Ngsk/Ngsk^* BMDMs showed higher phagocytic activity than B6-*Prnp^wt/wt^* macrophages (set as 100%). (right) The phagocytic activity of 129-*Prnp^Edbg/Edbg^* and 129-*Prnp^wt/wt^* macrophages was similar, even when two different macrophage/thymocyte (M:T) ratios were used (1:10 and 1:1; one-way ANOVA, Bonferroni's multiple comparisons test). Mean 129-*Prnp^wt/wt^* phagocytic rate at 1:10 M:T ratio was set as 100%. n.s., not significant; \*\*, P \< 0.005; \*\*\*, P \< 0.001; \*\*\*\*, P \< 0.0001. Error bars indicate SD. (C) STR analysis of Chr 2. Name and physical position of each STR marker (colored boxes) are indicated on the left. B6.129-*Prnp^ZrchI/ZrchI^* and B6.129-*Prnp^Ngsk/NgskI^* mice contained 129-derived genetic material flanking *Prnp*, whereas the markers flanking *Prnp* in 129-*Prnp^Edbg/Edbg^* and 129-*Prnp^wt/wt^* mice were identical. Data show representative mice of at least three animals analyzed per group.](JEM_20131274R_Fig3){#fig3}

To define the 129-derived regions flanking *Prnp*, we performed microsatellite analyses of Chr 2 in B6.129-*Prnp^−/−^* mice of the *ZrchI* and *Ngsk* lines. B6.129-*Prnp^ZrchI/ZrchI^* mice harbored 129-derived genomic material in a region of ≥48 Mbp flanking *Prnp* on Chr 2 (including *Sirpa*, *Mertk*, *Tyro3*, and *Thbs1* alleles) despite \>12 generations of backcross to B6 ([Fig. 3 C](#fig3){ref-type="fig"} and Fig. S2).

Compared with B6.129-*Prnp^ZrchI/ZrchI^*, B6.129-*Prnp^Ngsk/Ngsk^* mice contained a smaller 129-derived interval on Chr 2 ([Fig. 3 C](#fig3){ref-type="fig"}). These mice were homozygous for 129 alleles at *Sirpa* and *Mertk* and homozygous for B6 alleles at *Tyro3* and *Thbs1* ([Fig. 3 C](#fig3){ref-type="fig"}). Because B6.129-*Prnp^Ngsk/Ngsk^* mice retained the hyperphagocytic phenotype, variations in *Tyro3* or *Thbs1* alleles did not explain the differential phagocytic activity of *Prnp^wt/wt^* and *Prnp^−/−^* mice, excluding these two genes as candidates ([Fig. 3 C](#fig3){ref-type="fig"}).

We identified only one nonsynonymous single nucleotide polymorphism (SNP) in *Mertk^129^* versus *Mertk^B6^* alleles (Chr2:128776396, Att/Gtt). This SNP, previously reported in CD-1 mice (SNP accession no. rs27446326 from dbSNP Build 137), results in a conservative isoleucine-to-valine substitution within the transmembrane region (I516V) and is predicted by the SIFT algorithm ([@bib48]; [@bib36]) to be tolerated and unlikely to impact *Mertk* function. All disease-causing *MERTK* mutations identified so far in patients suffering from retinitis pigmentosa ([@bib21]), Leber congenital amaurosis ([@bib42]), or cancer ([@bib25]) were located in the extracellular or cytoplasmic but not in the transmembrane region. Moreover, one natural non--disease-causing variant in the transmembrane region has been reported in humans (I518V; [@bib21]; [@bib42]), which corresponds to the I516V variant in our mice, again suggesting that the variant identified in our mice is unlikely to impact *Mertk* function. Collectively, these findings suggested that *Sirpa^129^* homozygosity conferred differential levels of phagocytosis in otherwise genetically homogeneous mice and that the presence of at least one *Sirpa^B6^* allele reduced rates of phagocytosis compared with *Sirpa^129^* homozygotes.

*Sirpa^B6^* association with inhibition of phagocytosis
-------------------------------------------------------

We observed that some of our PrP^C^-overexpressing *tg*a*20* transgenic mice on a mixed B6129-*Prnp^ZrchI/ZrchI^* background ([@bib18]) were segregating *Sirpa^B6^* and *Sirpa^129^* alleles, likely reflecting an unintentional cross with B6-*Prnp^wt/wt^* breeders in the early days of this colony (unpublished data). We crossed B6129-*Prnp^ZrchI/ZrchI^ Sirpa^B6/B6^ tg*a*20^tg/tg^* mice to B6129-*Prnp^ZrchI/ZrchI^ Sirpa^129/129^* mice producing B6129-*Prnp^ZrchI/ZrchI^* littermates with all three combinations of *Sirpa^B6^* and *Sirpa^129^* alleles ([Fig. 4, A and B](#fig4){ref-type="fig"}). pMΦs from B6129-*Prnp^ZrchI/ZrchI^ Sirpa^129/129^* mice showed higher rates of phagocytosis ([Fig. 4, C and D](#fig4){ref-type="fig"}). Hence, compared with *Sirpa^129/129^*, a single *Sirpa^B6^* allele reduced phagocytosis rates in the absence of *Prnp*. These results supported the hypothesis that homozygosity for *Sirpa^129^* rather than *Prnp* deficiency was responsible for the hyperphagocytic phenotype of *Prnp^ZrchI/ZrchI^* mice.

![***Sirpa^B6^* allele segregates with enhanced inhibition of phagocytosis in the absence of *Prnp*.** (A) Breeding scheme applied to generate B6129-*Prnp^ZrchI/ZrchI^* mice containing *Sirpa^B6^* and *Sirpa^129^* alleles. B6129-*Prnp^ZrchI/ZrchI^ Sirpa^B6/B6^ tg*a*20^tg/tg^* mice (F~0~) were backcrossed to B6129-*Prnp^ZrchI/ZrchI^ Sirpa^129/129^* mice for two generations to produce B6129-*Prnp^ZrchI/ZrchI^* littermates, with all combinations of *Sirpa^B6^* and *Sirpa^129^* alleles (F~3~) used to assess phagocytic activity as in C. (B) RFLP analysis of *Sirpa* allelotypes (B6 vs. 129). Surprisingly, *tg*a*20* mice (first through third lanes) displayed combinations of *Sirpa^B6^* and *Sirpa^129^* alleles. The fourth through sixth lanes show B6129-*Prnp^ZrchI/ZrchI^* mice labeled in A (red arrows). Controls are reference DNA. All animals entering the study were analyzed. (C) Phagocytic hyperactivity of B6129-*Prnp^ZrchI/ZrchI^* pMΦs was associated with the *Sirpa^129/129^* allelotype. Data from three independent experiments (blue, black, and gray) normalized against mean B6129-*Prnp^ZrchI/ZrchI^Sirpa^B6/B6^* phagocytic rates. One-way ANOVA, Bonferroni's multiple comparisons test: \*, P \< 0.05; \*\*\*, P \< 0.001. Error bars indicate SD. (D) STR analysis documenting the boundaries of B6 versus 129-derived genome in Chr 2 of B6129-*Prnp^ZrchI/ZrchI^* with different combinations of *Sirpa* alleles (B6 vs. 129). Name and position of each STR marker (colored box) on Chr 2 are indicated on the left. Data show representative mice of at least three animals analyzed per group.](JEM_20131274R_Fig4){#fig4}

Inhibition of phagocytosis segregated with *Sirpa^B6^* in *Prnp^wt/wt^* mice
----------------------------------------------------------------------------

*Sirpa* alleles and *Prnp* ablation may impact phagocytosis independently of each other. We therefore asked whether different *Sirpa* alleles could modify phagocytosis in *Prnp^wt/wt^* mice. We genotyped 103 pups from B6.129-*Prnp^wt/ZrchI^ Sirpa^B6/129^* intercross mice for recombination between *Prnp* and *Sirpa* and observed two events producing a *Prnp^wt^*-*Sirpa^129^* and a *Prnp^ZrchI^*-*Sirpa^B6^* haplotype ([Fig. 5 A](#fig5){ref-type="fig"}). Mice carrying the original and the recombinant haplotypes were then bred to generate congenic mice with different *Prnp*-*Sirpa* haplotypes ([Fig. 5, B and C](#fig5){ref-type="fig"}).

![**Hyperphagocytosis is associated with the *Sirpa^129/129^* allelotype but not with *Prnp* gene dosage.** (A) Breeding scheme to generate recombinant congenic B6.129 mice with different combinations of *Prnp* (WT and ZrchI) and *Sirpa* (B6 and 129) alleles. B6.129-*Prnp^wt/ZrchI^* mice (F~1~) were intercrossed, and F~2~ offspring were screened for meiotic recombination between *Prnp* and *Sirpa*. 103 F~2~ mice with different combinations of *Prnp* genotypes and *Sirpa* allelotypes were obtained. Two mice (red frames) were found to carry the recombinant haplotype, *Prnp^wt^*-*Sirpa^129^* and *Prnp^ZrchI^*-*Sirpa^B6^* and were interbred to generate B6.129-*Prnp^ZrchI/ZrchI^* and B6.129-*Prnp^wt/wt^* mice homozygous for *Sirpa^B6^* or *Sirpa^129^* alleles. (B) RFLP analysis to discriminate between *Sirpa^129^* and *Sirpa^B6^*. B6.129-*Prnp^wt/wt^* (first, third, and fifth lanes) and B6.129-*Prnp^ZrchI/ZrchI^* (second, fourth, and sixth lanes) mice with different combinations of *Sirpa^129^* and *Sirpa^B6^* alleles. Controls are reference DNA. All animals entering the study were analyzed. (C) Protein sequence variants (yellow) in SIRPα Ig-like variable domain (IgV). Homozygous recombinant congenic B6.129 mice displayed four combinations of *Prnp*-*Sirpa* haplotypes (black boxes). Blue boxes show SIRPα sequence of reference B6 and 129/Sv strains. For each group one mouse was analyzed. (D) *Sirpa^129/129^*, but not *Prnp^−/−^*, was associated with hyperphagocytosis in pMΦs from congenic B6.129 mice. Data are from two independent experiments (blue and black); phagocytosis rates were normalized against B6.129 *Prnp^wt/wt^ Sirpa^B6/B6^*. One-way ANOVA, Bonferroni's multiple comparisons post-test: \*, P \< 0.05; \*\*\*\*, P \< 0.0001. Error bars indicate SD. (E) Recombination breakpoints between *Prnp* and *Sirpa* in congenic B6.129 mice. For each STR marker (colored box), name and position on Chr 2 are indicated on the left. Data show representative mice of at least three animals analyzed per group.](JEM_20131274_Fig5){#fig5}

The various *Prnp*-*Sirpa* haplotypes did not affect the frequency of macrophages in peritoneal lavages, nor did *Sirpa* allelotypes affect PrP^C^ expression ([Fig. 6, A--C](#fig6){ref-type="fig"}). Also, we did not observe differences in *Sirpa* mRNA levels between pMΦs from B6.129-*Prnp^ZrchI/ZrchI^* and B6.129-*Prnp^wt/wt^* mice (375.60 vs. 356.34 fragments per kilobase of transcript per million mapped reads \[FPKM\], respectively, P = 0.73) or SIRPα protein levels in mice with different *Prnp*-*Sirpa* haplotypes ([Fig. 6 D](#fig6){ref-type="fig"}). These results excluded any influence of *Prnp* or *Sirpa* alleles on the expression of each other.

![***Sirpa* allelotype does not influence pMΦ abundance or PrP^C^ and SIRPα expression.** (A) Peritoneal lavages were gated for nucleated cells (left), and the percentage of F4/80^+^ cells was assessed (middle panel, right peak). (right) Overlay of histograms of F4/80 (dark blue), isotype antibody (light blue), and unstained peritoneal cells (gray) confirming the specificity of the staining. (B) Percentage of F4/80^+^ macrophages in peritoneal lavage cells of experimental mice. The dotted lines delineate individual experiments in which groups of mice (*n* = 3--10 for each haplotype) were analyzed. Error bars indicate SD. (C) PrP^C^ ELISA analysis of pMΦ lysates showed no difference (n.s.) in PrP^C^ levels between B6.129-*Prnp^wt/wt^* mice with different *Sirpa* allelotypes. Two-tailed unpaired Student's *t* test: P = 0.241; *n* = 3--4 for each haplotype. n.d., not detectable. (D) Unchanged expression of the SIRPα cytoplasmic tail (CT) in cultured pMΦ lysates as quantified to actin levels. SHPS-1 KO macrophage lysates lacking the cytosolic tail of SIRPα were used as negative control. One-way ANOVA: n.s., not significant; P = 0.27; *n* = 3--4 for each haplotype. Horizontal bars indicate mean.](JEM_20131274_Fig6){#fig6}

In congenic B6.129 mice with different combinations of *Prnp* and *Sirpa* alleles (WT and ZrchI, B6 and 129, respectively), hyperphagocytosis segregated with *Sirpa^129/129^* irrespectively of the *Prnp* status ([Fig. 5, D and E](#fig5){ref-type="fig"}). We compared phagocytosis by BMDMs isolated from congenic C.129-*Prnp^ZrchI/ZrchI^* mice with different combinations of *Prnp* and *Sirpa* alleles ([Fig. 7, A--C](#fig7){ref-type="fig"}). In line with our findings with congenic B6.129 mice, a higher phagocytosis rate correlated with *Sirpa^129/129^* independently of the *Prnp* alleles ([Fig. 7, D and E](#fig7){ref-type="fig"}). Together, these results exclude a role for PrP^C^ and support *Sirpa* polymorphisms as a major regulator of phagocytosis in mouse strains carrying either WT or deleted *Prnp* alleles.

![**Phagocytic activity level is associated with *Sirpa^129/129^* allelotype but not with *Prnp* gene dosage also in C.129 congenic mice.** (A) Breeding scheme to generate recombinant congenic C.129 mice with different combinations of *Prnp* (WT and ZrchI) and *Sirpa* (C and 129) alleles. C.129-*Prnp^wt/ZrchI^* mice (F~1~) were intercrossed, and the occurrence of meiotic recombination between *Prnp* and *Sirpa* was assessed in the F~2~ offspring. 243 F~2~ mice with different combinations of *Prnp* genotypes and *Sirpa* allelotypes were obtained. Four mice (red frames) were found to carry a recombinant haplotype, and selected ones were bred to generate C.129-*Prnp^ZrchI/ZrchI^* and C.129-*Prnp^wt/wt^* mice homozygous for *Sirpa^C^* or *Sirpa^129^* alleles. (B) RFLP analysis used to discriminate *Sirpa^129^* from *Sirpa^C^* alleles. C.129-*Prnp^wt/wt^* (first, third, and fifth lanes) and C.129-*Prnp^ZrchI/ZrchI^* (second, fourth, and sixth lanes) mice with different combinations of *Sirpa^129^* and *Sirpa^C^* alleles. Controls are reference DNA. All animals entering the study were analyzed. (C) Protein sequence alignment of mouse SIRPα Ig-like variable domain (IgV) illustrates recombinant congenic C.129 mice with different combinations of *Prnp* and *Sirpa^129^* versus *Sirpa^C^* (gray border). Blue boxes are SIRPα protein reference sequences for the B6, 129/Sv, and C strains (yellow: polymorphisms). For each group one mouse was analyzed. (D) *Sirpa^129/129^* allelotype, but not the absence of *Prnp*, was associated with hyperphagocytosis of BMDMs in congenic C.129 mice. Data are from three independent experiments (blue, black, and gray). Mean phagocytosis rates of C.129 *Prnp^ZrchI/ZrchI^ Sirpa^B6/B6^* were set as 100%. One-way ANOVA, Bonferroni's multiple comparison post-test: \#, P = 0.075; \*\*\*\*, P \< 0.0001. Error bars indicate SD. (E) STR analysis documents the result of trans-allelic meiotic recombination between *Prnp* and *Sirpa*. Blue dashed line indicates the location of *Prnp* and *Sirpa*. For each STR marker (colored box), name and position on Chr 2 are indicated on the left. Data show representative mice of at least three animals analyzed per group.](JEM_20131274_Fig7){#fig7}

DISCUSSION
==========

In the 1990s the *Prnp* gene became an extremely popular target among mouse geneticists and rapidly advanced to one of the most frequently inactivated elements of the mouse genome. As a result, we have indeed identified at least seven published mouse lines derived from independent gene-targeting events, all of which were analyzed in the present study. Remarkably, we discovered that all of these lines suffer from the same set of confounders when kept as congenic: a 129-derived genomic region sporting functionally impactful polymorphisms.

The alleged control of phagocytosis of apoptotic cells by *Prnp* was critically questioned when we found that, in contrast to congenic B6.129- or C.129-*Prnp^ZrchI/ZrchI^* and B6.129-*Prnp^Ngsk/Ngsk^* mice, co-isogenic 129-*Prnp^Edbg/Edbg^* mice did not display a hyperphagocytic phenotype. Moreover, microsatellite-assisted breeding of B6129-*Prnp^ZrchI/ZrchI^* mice revealed the existence of a 129-derived Chr 2 segment which, when homozygous, correlated with a higher rate of phagocytosis independent of *Prnp*. These data suggested that *Prnp* does not impact phagocytosis and that such conclusions in previous studies resulted from unrecognized polymorphic flanking genes ([@bib14]). Detailed genomic, transcriptomic, and functional analysis of candidate genes in the introgressed 129-derived region in B6.129-*Prnp^ZrchI/ZrchI^* mice supported a focus on the well-characterized inhibitor of phagocytosis *Sirpa*, whose polymorphisms alter this phenotype ([@bib71]; [@bib40]; [@bib70]). Indeed, *Sirpa^129^*, rather than *Prnp^−^*, segregated with increased phagocytosis.

B6.129-*Prnp^ZrchI/ZrchI^* and B6.129-*Prnp^wt/wt^* macrophages displayed sequence variations, or differential expression, of several other genes in addition to *Sirpa*. In particular, *Mertk* ([@bib63]), *Tyro3* ([@bib64]), and *Thbs1* ([@bib22]), which participate in phagocytosis and are linked to *Prnp*, were polymorphic between the two strains. However, the genetic and functional considerations detailed above suggested that they were unlikely candidates.

In our study, we have used mouse genetics to investigate the role of PrP^C^ and its polymorphic flanking genes in modulating phagocytosis of apoptotic cells. Compared with other experimental approaches, including gene silencing and overexpression of exogenously introduced genes, formal genetics has the advantage of assessing the differential impact of physiological versus absent expression of the gene under scrutiny. Moreover, silencing or overexpressing *Sirpa*, or other modulators of phagocytosis, could alter the delicate balance between pro- and antiphagocytic signals ([@bib27]) and impact phagocytosis independently of whether this modulator is responsible for the difference between *Prnp^−/−^* and *Prnp^+/+^* macrophages.

Enzymatic removal of PrP^C^ from macrophage surface through phosphoinositol phospholipase C was reported to result in an increased phagocytosis of apoptotic cells, seemingly confirming the role of PrP^C^ in this process ([@bib14]). However, this treatment generically affects all glycosylphosphatidylinositol-anchored proteins, many of which are involved in the control of phagocytosis ([@bib16]; [@bib7]; [@bib54]; [@bib32]; [@bib55]; [@bib9]; [@bib13]). Therefore, it is questionable whether this effect is directly mediated by loss of surface PrP^C^.

Our study focused on the presumed role of PrP^C^ in phagocytosis of apoptotic cells. Phagocytosis of zymosan particles and latex beads were also reported to be influenced by *Prnp* using primary macrophages or immortalized cell lines derived from *Prnp^−/−^* and *Prnp^+/+^* mice ([@bib14]; [@bib50]; [@bib76]). Our results raise the question of whether *Sirpa* polymorphisms may affect the responses to zymosan or phagocytosis of latex beads as well.

The co-segregation of *Sirpa^129^* with *Prnp^−^* in all the *Prnp^−/−^* lines examined has implications beyond the control of phagocytosis. Because the *Sirpa* sequence of most mouse strains used for backcrossing of *Prnp^−/−^* mice (B6, BALB/c, and FVB) differs from 129 mice ([@bib62]; [@bib71]), *Sirpa* is a potential confounder in most studies of *Prnp^−/−^* mice. Importantly, the expression pattern of *Sirpa* mirrors that of *Prnp* and includes myeloid cells, neurons, and pancreatic β cells ([@bib43]; [@bib46]). Finally, PrP^C^-deficient mice share numerous subtle phenotypes with *Sirpa*-ablated mice, including neuroimmunological ([@bib73]; [@bib74]), behavioral ([@bib49]; [@bib53]; [@bib20]), and metabolic phenotypes ([@bib34]; [@bib69]). These observations suggest that additional phenotypes attributed to *Prnp* may actually reflect the effects of *Sirpa* polymorphisms.

Based on studies with *Prnp^−/−^* mice, PrP^C^ has been recently reported to either induce or inhibit autophagy ([@bib51], [@bib52]; [@bib35]) and to be indispensable or dispensable to mediate Aβ toxicity ([@bib39]; [@bib2]; [@bib6]; [@bib24]; [@bib33]; [@bib10]; [@bib38]; [@bib75]). At least some of these controversies could reflect the effect of polymorphic *Prnp*-flanking genes, and these findings merit critical reconsideration in light of our data.

The risk of flanking-gene problems can be reduced by reversing the phenotype of gene-targeted mice through transgenetic restoration of gene expression ([@bib78]). With *Prnp*, this was often done by using PrP^C^-overexpressing *tg*a*20* mice, which were generated from *Prnp^ZrchI/ZrchI^* mice and subsequently distributed to many laboratories. However, we found that the *tg*a*20* colony was contaminated with multiple combinations of *Sirpa* alleles early after its establishment. Hence the rescue of *Prnp* deficiency through a *tg*a*20* allele does not necessarily prove that the observed changes in phenotype are PrP^C^ dependent.

It has been long suspected that genes flanking targeted loci may confound the interpretation of KO experiments ([@bib65]; [@bib23]). Recommendations for breeding schemes and genetic quality control to avoid this problem were formulated ([@bib78]; [@bib59]; [@bib12]) but rarely implemented ([@bib28]). Consequently, reports of flanking gene effects are anecdotal and rely on the demonstration that a KO mouse phenotype is lost upon crossing to other strains backgrounds and reduction in length of the 129-derived region flanking the targeted locus ([@bib31]; [@bib15]; [@bib17]). Our findings provide an alternative mechanism underlying prior specific claims in the prion field and strengthen the requirement for rigorous genetic, genomic, and functional analyses to support the assignment of specific phenotypes to targeted mutations in mice.

MATERIALS AND METHODS
=====================

### Mice.

The following mice were analyzed: *Prnp^ZrchI/ZrchI^* mice ([@bib5]) on a mixed B6129 background or backcrossed to B6 for \>12 generations or to C for \>17 generations and congenic WT B6 and C mice purchased from Harlan or Charles River or bred in house; *Prnp^Ngsk/Ngsk^* mice ([@bib61]) extensively backcrossed to B6; *Prnp^Edbg/Edbg^* mice on a pure 129/Ola background ([@bib45]) and co-isogenic WT 129/Ola mice; *Prnp^ZrchII/ZrchII^* mice ([@bib60]) on a mixed B6129 background; *Prnp^GFP/GFP^* mice ([@bib26]) backcrossed to B6 for 10 generations; *tg*a*20* mice ([@bib18]) on a mixed B6129 *Prnp^ZrchI/ZrchI^* background; and SHPS-1 ([@bib29]) backcrossed to B6 for \>5 generations. Genotype of mice was verified as indicated in the original description of each line ([Table 1](#tbl1){ref-type="table"}). To introduce *Sirpa^B6^* into B6129-*Prnp^ZrchI/ZrchI^* mice, B6129-*Prnp^ZrchI/ZrchI^ Sirpa^B6/B6^ tg*a*20^tg/tg^* mice were crossed with B6129-*Prnp^ZrchI/ZrchI^ Sirpa^129/129^* mice ([Fig. 4 A](#fig4){ref-type="fig"}). To generate congenic B6.129-*Prnp^ZrchI/ZrchI^* and *Prnp^wt/wt^* mice with all possible combinations of *Sirpa^B6^* and *Sirpa^129^* alleles, B6.129-*Prnp^wt/ZrchI^ Sirpa^B6/129^* mice were intercrossed, and recombination events between *Prnp* and *Sirpa* loci were identified by *Prnp* genotyping and RFLP analysis of *Sirpa* exon 2 in the offspring ([Fig. 5, A and B](#fig5){ref-type="fig"}). Mice with a recombinant haplotype (referred to as obligate carriers) were further crossed. The same approach was followed to generate congenic C.129-*Prnp^ZrchI/ZrchI^* and *Prnp^wt/wt^* mice with all possible combinations of *Sirpa^C^* and *Sirpa^129^* alleles ([Fig. 7, A and B](#fig7){ref-type="fig"}). All animal experiments were performed in compliance with the Swiss Animal Protection Law, under the approval of the Veterinary office of the Canton Zurich.

### Allele discrimination analysis.

To distinguish strain-specific alleles, PCR-RFLP analysis (*Sirpa*, *Tyro3*, and *Thbs1*) or sequencing (*Mertk*) were performed using primers and restriction enzymes as detailed in [Table S4](http://www.jem.org/cgi/content/full/jem.20131274/DC1){#supp7}.

### Phagocytosis assay with pMΦs.

On day 0, peritoneal cells were collected from age- and gender-matched adult mice according to standard methods ([@bib19]), resuspended to 2.2 × 10^6^ in 5 ml DMEM (Gibco) with 10% FBS (Gibco), 1% GlutaMAX (Gibco), and antibiotics, plated in one-well slide chambers (Falcon; BD), and incubated at 37°C. After 2 h, nonadhering cells were removed and remaining cells (referred to as cultured pMΦs) were kept overnight in culture. On day 1, thymocytes were harvested from 3--8-wk-old mice of the same background as the genotypes under investigation, incubated for 3 h at 37°C in the presence of 1 µM dexamethasone to induce apoptosis, washed, and added to the cultured pMΦs at different ratios for 1 h. For each experimental group, technical replicates (at least duplicates) were performed. Cells were washed, fixed with formalin, and stained with May-Grünwald-Giemsa. Slides were randomized and scanned with NanoZoomer (Hamamatsu Photonics), random fields (50 fields/slide) were generated, and phagocytosis rate was assessed using in-house--developed software. The same operator blinded to experimental groups validated all software-analyzed slides. For each technical replicate, \>800 cells were evaluated (indicated as a dot in the graphs). Phagocytosis rate was defined as the percentage of macrophages having at least one apoptotic body.

### Phagocytosis assay with BMDMs.

On day 0, femurs were collected from age- and gender-matched adult mice and flushed with RPMI1640 medium (Gibco) containing 10% FBS (Gibco), 1% GlutaMAX (Gibco), and antibiotics. BM cells were plated into 6-well plates at 2 × 10^6^/well in 3 ml of culture medium containing 10 ng/ml of macrophage colony stimulation factor (Invitrogen) and cultured overnight at 37°C. On day 1, cells were transferred to new 6-well plates to remove loosely adherent stroma-like cells. On day 6, cells were harvested, adjusted to 5 × 10^5^ cells in 500 µl, and plated into 24-well plates. Apoptotic thymocytes (see above) were suspended at 10^6^/ml in PBS and labeled with 20 ng/ml of the pH-sensitive dye pHrodo red, SE (Invitrogen) for 30 min at room temperature and washed, and 500 µl of cell suspension was added to BMDM culture for 1 h at 37°C. After washing, BMDMs were harvested with Accutase (Invitrogen) and gentle scraping and stained with FITC-labeled anti-CD11b or isotype control antibody (BD), and rate of phagocytosis was analyzed by flow cytometry as the percentage of pHrodo positivity among CD11b^+^ cells. At least 10,000 events were acquired in the living gate.

### Genome-wide and Chr 2 short tandem repeat (STR) analysis.

Genome-wide STR analysis was performed as previously described ([@bib4]). In brief, purified genomic DNA (gDNA) was amplified using multiplex PCR with fluorescently labeled primers (FAM, NED, and VIC; Applied Biosystems), diluted, denatured, and subjected to capillary electrophoresis on a 3130*xl* Genetic Analyzer (Applied Biosystems). Various mouse strains were used for calibration. Peak detection, binning, and allele calling were performed using the GeneMapper software (Applied Biosystems) in combination with in-house--developed software.

### High-resolution STR genotyping on Chr 2.

Novel microsatellite markers were generated as previously described ([@bib30]; primer sequences in Table S4). DNA was amplified for 35 cycles: 30 s at 94°C, 30 s at 55°C, and 1 min at 72°C using Multiplex Master Mix (QIAGEN). The PCR product was diluted 1/20, and 1 µl mixed with a 10-µl mixture containing formamide and a 500LIZ size standard. Samples were resolved on the 3730*xl* DNA Analyzer (Applied Biosystems). Alleles were sized, in comparison with standards, by viewing electropherograms in GeneMapper.

### Library preparation for RNA sequencing.

Total RNA was isolated from cultured pMΦs using the RNeasy mini kit (QIAGEN), snap frozen, and kept at −80°C until further analysis. RNA quality was determined with Qubit (1.0) Fluorometer (Life Technologies) and Bioanalyzer 2100 (Agilent Technologies). Only samples with a 260 nm/280 nm ratio between 1.8 and 2.1 and a 28S/18S ratio between 1.5 and 2 were further processed. The TruSeq RNA Sample Prep kit v2 (Illumina) was used in the succeeding steps. In brief, total RNA samples (1 µg) were poly A enriched and reverse transcribed into double-stranded cDNA. TruSeq adapters were ligated to double-stranded cDNA. Fragments containing TruSeq adapters on both ends were selectively enriched with PCR. Quality and quantity of enriched libraries were validated using Qubit (1.0) Fluorometer and Caliper GX LabChip GX (Caliper Life Sciences). The product is a smear with a mean fragment size of ∼260 bp. Libraries were normalized to 10 nM in Tris-Cl 10 mM, pH 8.5, with 0.1% (vol/vol) Tween 20.

### Cluster generation and RNA sequencing.

TruSeq PE Cluster kit v3-cBot-HS (Illumina) was used for cluster generation using 2 pM of pooled normalized libraries on the cBOT. Sequencing was performed on Illumina HiSeq 2000 paired-end at 2 × 101 bp using the TruSeq SBS kit v3-HS (Illumina). Sequences have been deposited in NCBI Sequence Read Archive under SRA identifier no. SRP029761.

### RNA sequencing data analysis.

Reads were quality-checked with FastQC. Low-quality ends were clipped (3 bases from the start, 10 bases from the end). Trimmed reads were aligned to the reference genome and transcriptome (FASTA and GIFF files, respectively, downloaded from the UCSC mm10 database) with TopHat version 2.0.6. TopHat was run with the following options: mate inner distance set to 30, the corresponding SD to 100, and maximum 10 multi-hits were allowed in the alignment. Reads that did not align at the first attempt were split into 25-base-long sections on which a second attempt of alignment was performed. In B6.129-*Prnp^ZrchI/ZrchI^* pMΦs, all reads mapping to *Prnp* between BstEII and EcoRI restriction sites in exon 3 and in the 3′ UTR, respectively, possibly representing a fused mRNA containing *neo* and residual *Prnp*, reported in the brain of these mice ([@bib5]), were excluded from the analysis. Polymorphisms were detected using GATK version 2.1.8 using the following options: baq Gap open penalty (whole-genome analysis) set to 30; minimum consensus coverage to genotype indels set to 8 (default: 5); minimum base quality score and minimum variants phred score set to 15. Variants were annotated using snpEFF version 3.0, and distribution of the reads across genomic isoform expression was quantified using RSEM ([@bib41]). Cufflinks version 2.0.2 and differentially expressed genes listed with its utility Cuffdiff using default options were used.

All remaining data and statistical analyses, formatting, and picture generating were produced via in-house R-scripts (R version 2.15.2). The SIFT algorithm with default settings was used to predict the impact of a nonsynonymous SNP in *Mertk* ([@bib36]).

### *Sirpa* open reading frame sequencing.

Cultured pMΦ cDNA and gDNA were used to PCR amplify and sequence coding and untranslated regions of mouse *Sirpa* as previously described ([@bib71]). Primers (Microsynth) are listed in Table S4. For *Prnp^Rkn/Rkn^* mice, sequencing was performed on gDNA obtained from Institute of Physical and Chemical Research, Japan, and from cDNA isolated from *Prnp^Rkn/Rkn^*--derived hippocampal like cells (HpL3-4; [@bib37]). For *Prnp^Rcm0/Rcm0^* mice, only gDNA from one single mouse was available, and sequencing was performed only on the highly polymorphic exon 2 of *Sirpa*.

### Western blotting.

Western blotting on pMΦ cell lysates was performed according to standard methods using polyclonal anti-*Sirpa* cytoplasmic tail (CT) antibody (IMGENEX).

### PrP^C^-ELISA.

PrP^C^ was quantified in cultured pMΦ lysates by sandwich ELISA as described previously using POM1 and POM2 antibodies ([@bib56]).

### Flow cytometry analysis.

Freshly isolated peritoneal cells were incubated with FITC-labeled anti-F4/80 or isotype control antibody (BD). Thymocyte apoptosis was assessed using the FITC Annexin V Apoptosis Detection kit II (BD). Flow cytometry was performed using a FACSCalibur or a FACSCanto (BD), and data were acquired with CellQuest Pro or FACSDiva software, respectively, and analyzed with FlowJo software (Tree Star).

### Statistical analysis.

Comparisons of phagocytic activity of macrophages of different genotypes were performed using one-way ANOVA and Bonferroni's multiple comparison post-test (α level 0.05) or two-tailed unpaired Student's *t* test using Prism software (GraphPad Software). The statistical test, p-values, and the *n* for each statistical analysis are indicated in each of the corresponding figure legends.

### Online supplemental material.

Figs. S1 and S2 illustrate the genomic characterization of experimental mice. Tables S1 and S2, included as separate PDF files, list relevant genes identified by RNA sequencing. Table S3 lists allelotypes of experimental mice. Table S4 lists primer sequences and restriction enzymes used for genetic analysis. Online supplemental material is available at <http://www.jem.org/cgi/content/full/jem.20131274/DC1>.

Supplementary Material
======================

###### Supplemental Material

This study is dedicated to the memory of Prof. Marek Fischer, who generated the *tg*a*20* transgenic mice.

We thank A.D. Steele, W.S. Jackson, S. Lindquist, T. Onodera, H. Baybutt, N.A. Mabbott, J. Manson, L. Mucke, S.M. Strittmatter, M. Lötscher, R. Zinkernagel, H. Ohnishi, T. Matozaki, and Institute of Physical and Chemical Research, Japan, for providing mice and DNA samples; W.S. Jackson, D. Rossi, and D. Melton for information on *Prnp^−/−^* lines not included in the original descriptions of the lines; C. Aquino Fournier for RNA sequencing, D. Zimmermann for DNA sequencing; A. Wong for assistance with fine mapping; M. Heikenwaelder, T. Suter, R. Linden, H. Takizawa, Y. Saito, P. Pelczar, S. Hornemann, M. Hermann, S. Sorce, A.M. Callela, and S. Lesne for critical discussions; M. Bieri and N. Wey for software development; and Y. Fuhrer, M. Delic, P. Schwarz, R. Moos, L. Varrica, C. Tostado, and K. Schreiber for excellent technical help.

This work was supported by grants from Collegio Ghislieri, Pavia, Italy (to M. Nuvolone); the Swiss National Science Foundation (SNF; to V. Kana); the Canadian Institutes of Health Research (CIHR; \#64216), Genome Canada, and the Juvenile Diabetes Research Foundation (\#17-2011-520; to J.S. Danska); and the European Union (LUPAS, PRIORITY), the SNF, the Clinical Research Focus Program of the University of Zurich, the Foundation Alliance BioSecure, and the Novartis Research Foundation and an Advanced Grant of the European Research Council (to A. Aguzzi).

The authors have no conflicting financial interests.

Abbreviations used:Chr 2chromosome 2ESembryonic stemgDNAgenomic DNApMΦperitoneal macrophageRFLPrestriction fragment length polymorphismSNPsingle nucleotide polymorphismSTRshort tandem repeat

[^1]: M. Nuvolone, V. Kana, and G. Hutter contributed equally to this paper.
